Roth Capital Weighs in on Nuvectis Pharma FY2028 Earnings

Nuvectis Pharma, Inc. (NASDAQ:NVCT - Free Report) - Analysts at Roth Capital cut their FY2028 earnings estimates for shares of Nuvectis Pharma in a note issued to investors on Tuesday, February 25th. Roth Capital analyst J. Aschoff now forecasts that the company will post earnings of $3.23 per share for the year, down from their previous forecast of $3.61. The consensus estimate for Nuvectis Pharma's current full-year earnings is ($1.01) per share. Roth Capital also issued estimates for Nuvectis Pharma's FY2029 earnings at $4.24 EPS.

Separately, HC Wainwright reduced their price objective on shares of Nuvectis Pharma from $21.00 to $11.00 and set a "buy" rating on the stock in a research note on Tuesday, February 25th.

Nuvectis Pharma Price Performance

Shares of NASDAQ NVCT traded down $0.55 during mid-day trading on Thursday, hitting $6.14. The company's stock had a trading volume of 105,525 shares, compared to its average volume of 114,471. Nuvectis Pharma has a one year low of $4.44 and a one year high of $12.10. The company's fifty day simple moving average is $6.30 and its 200-day simple moving average is $6.41. The stock has a market cap of $143.63 million, a price-to-earnings ratio of -5.29 and a beta of 0.22.

Nuvectis Pharma (NASDAQ:NVCT - Get Free Report) last issued its quarterly earnings results on Tuesday, March 4th. The company reported ($0.36) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.28) by ($0.08).

Remove Ads

Insider Transactions at Nuvectis Pharma

In other Nuvectis Pharma news, major shareholder Marlio Charles Mosseri bought 240,000 shares of the firm's stock in a transaction on Friday, February 7th. The stock was purchased at an average cost of $5.00 per share, with a total value of $1,200,000.00. Following the completion of the purchase, the insider now owns 2,884,121 shares in the company, valued at approximately $14,420,605. The trade was a 9.08 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. In the last ninety days, insiders purchased 261,500 shares of company stock worth $1,300,825. 35.78% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Nuvectis Pharma

Several institutional investors and hedge funds have recently modified their holdings of NVCT. Baldwin Wealth Partners LLC MA boosted its holdings in shares of Nuvectis Pharma by 104.4% in the fourth quarter. Baldwin Wealth Partners LLC MA now owns 355,961 shares of the company's stock valued at $1,926,000 after buying an additional 181,831 shares during the period. Marshall Wace LLP boosted its stake in Nuvectis Pharma by 191.0% in the 4th quarter. Marshall Wace LLP now owns 124,571 shares of the company's stock worth $674,000 after purchasing an additional 81,757 shares during the period. Geode Capital Management LLC boosted its stake in Nuvectis Pharma by 49.8% in the 3rd quarter. Geode Capital Management LLC now owns 79,716 shares of the company's stock worth $501,000 after purchasing an additional 26,489 shares during the period. Forbes J M & Co. LLP raised its position in Nuvectis Pharma by 21.9% in the 4th quarter. Forbes J M & Co. LLP now owns 59,000 shares of the company's stock valued at $319,000 after buying an additional 10,599 shares during the last quarter. Finally, Iridian Asset Management LLC CT acquired a new stake in shares of Nuvectis Pharma in the third quarter valued at approximately $348,000. 96.77% of the stock is currently owned by institutional investors and hedge funds.

Nuvectis Pharma Company Profile

Nuvectis Pharma, Inc, a biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious unmet medical needs in oncology. The company's lead product candidate is NXP800, a novel small molecule that is in Phase 1b clinical trials for the treatment of patients with platinum-resistant, ARID1a-mutated ovarian carcinoma.